The Adenosine Analogue NITD008 has Potent Antiviral Activity against Human and Animal Caliciviruses
Open Access
Abstract
The widespread nature of calicivirus infections globally has a substantial impact on the health and well-being of humans and animals alike. Currently, the only vaccines approved against caliciviruses are for feline and rabbit-specific members of this group, and thus there is a growing effort towards the development of broad-spectrum antivirals for calicivirus infections. In this study, we evaluated the antiviral activity of the adenosine analogue NITD008 in vitro using three calicivirus model systems namely; feline calicivirus (FCV), murine norovirus (MNV), and the human norovirus replicon. We show that the nucleoside analogue (NA), NITD008, has limited toxicity and inhibits calicivirus replication in all three model systems with EC50 values of 0.94 μM, 0.91 µM, and 0.21 µM for MNV, FCV, and the Norwalk replicon, respectively. NITD008 has a similar level of potency to the most well-studied NA 2′-C-methylcytidine in vitro. Significantly, we also show that continual NITD008 treatment effectively cleared the Norwalk replicon from cells and treatment with 5 µM NITD008 was sufficient to completely prevent rebound. Given the potency displayed by NITD008 against several caliciviruses, we propose that this compound should be interrogated further to assess its effectiveness in vivo. In summary, we have added a potent NA to the current suite of antiviral compounds and provide a NA scaffold that could be further modified for therapeutic use against calicivirus infections.Keywords
Funding Information
- National Health and Medical Research Council (APP1083139, APP1123135)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (POS DOC 88881.120009/2016-01)
This publication has 47 references indexed in Scilit:
- Diagnosis and prevention of RHVD2 infectionVeterinary Record, 2018
- Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical TrialThe Journal of Infectious Diseases, 2017
- Rapid Responses to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: A Randomized Controlled TrialThe Journal of Infectious Diseases, 2016
- Global Economic Burden of Norovirus GastroenteritisPLOS ONE, 2016
- Aetiology-Specific Estimates of the Global and Regional Incidence and Mortality of Diarrhoeal Diseases Commonly Transmitted through FoodPLOS ONE, 2015
- Serological Correlates of Protection against a GII.4 NorovirusClinical and Vaccine Immunology, 2015
- Norovirus Vaccine Against Experimental Human GII.4 Virus Illness: A Challenge Study in Healthy AdultsThe Journal of Infectious Diseases, 2014
- Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2014
- Antiviral strategies to control calicivirus infectionsAntiviral Research, 2010
- Feline calicivirusVeterinary Research, 2007